Ed Arce
Stock Analyst at WestPark Capital
(4.19)
# 492
Out of 5,044 analysts
471
Total ratings
46.37%
Success rate
16.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $24 → $28 | $10.44 | +168.20% | 13 | Sep 30, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $29.81 | +0.64% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $12 | $0.97 | +1,136.99% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $4.72 | +1,488.98% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $9.88 | +507.29% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $3.09 | +142.72% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $5.27 | +146.68% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $5.09 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $1.30 | +361.54% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $9.24 | +657.58% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $30.89 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $6.30 | +3,709.52% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.78 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $8.24 | +288.35% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $105.14 | -66.71% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $75 | $54.00 | +38.89% | 25 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 → $21 | $14.84 | +41.56% | 22 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $70.22 | +2.53% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $429.18 | -5.63% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $5.11 | +7.74% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $34.77 | +173.22% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $4.20 | +209.52% | 18 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.58 | +9.17% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $36.14 | +32.82% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $8.55 | -12.28% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.66 | +654.15% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $12.64 | +2.85% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.81 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $29.94 | -16.49% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.47 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $19.23 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $34.93 | -79.96% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $35.44 | -40.74% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.21 | - | 2 | Feb 15, 2017 |
Enanta Pharmaceuticals
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $10.44
Upside: +168.20%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $29.81
Upside: +0.64%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $12
Current: $0.97
Upside: +1,136.99%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $4.72
Upside: +1,488.98%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $9.88
Upside: +507.29%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $3.09
Upside: +142.72%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $5.27
Upside: +146.68%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $5.09
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $1.30
Upside: +361.54%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $9.24
Upside: +657.58%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $30.89
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $6.30
Upside: +3,709.52%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.78
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $8.24
Upside: +288.35%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $105.14
Upside: -66.71%
Mar 3, 2025
Maintains: Buy
Price Target: $72 → $75
Current: $54.00
Upside: +38.89%
Feb 28, 2025
Reiterates: Buy
Price Target: $29 → $21
Current: $14.84
Upside: +41.56%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $70.22
Upside: +2.53%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $429.18
Upside: -5.63%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $5.11
Upside: +7.74%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $34.77
Upside: +173.22%
Feb 7, 2025
Reiterates: Buy
Price Target: $13
Current: $4.20
Upside: +209.52%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.58
Upside: +9.17%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $36.14
Upside: +32.82%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $8.55
Upside: -12.28%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.66
Upside: +654.15%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $12.64
Upside: +2.85%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.81
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $29.94
Upside: -16.49%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.47
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $19.23
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $34.93
Upside: -79.96%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $35.44
Upside: -40.74%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.21
Upside: -